BBR Partners LLC bought a new stake in FibroGen, Inc (NASDAQ:FGEN) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 5,556 shares of the biopharmaceutical company’s stock, valued at approximately $299,000.

Other hedge funds have also added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in shares of FibroGen in the second quarter valued at approximately $128,000. Oppenheimer Asset Management Inc. grew its holdings in FibroGen by 112.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 2,336 shares during the period. Ameritas Investment Partners Inc. grew its holdings in FibroGen by 15.4% during the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 696 shares during the period. Teacher Retirement System of Texas bought a new position in FibroGen during the third quarter valued at $299,000. Finally, SG Americas Securities LLC grew its holdings in FibroGen by 6.5% during the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 412 shares during the period. 57.42% of the stock is owned by institutional investors.

Several brokerages have weighed in on FGEN. Mizuho began coverage on FibroGen in a report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective for the company. Stifel Nicolaus reissued a “buy” rating and set a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Jefferies Group reissued a “buy” rating and set a $75.00 price objective on shares of FibroGen in a report on Tuesday, September 12th. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub lowered FibroGen from a “hold” rating to a “sell” rating in a report on Thursday. Two analysts have rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $65.67.

In related news, Director Gerald Lema bought 3,500 shares of the company’s stock in a transaction on Monday, December 4th. The shares were purchased at an average price of $46.70 per share, for a total transaction of $163,450.00. Following the completion of the transaction, the director now directly owns 3,500 shares in the company, valued at approximately $163,450. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jorma Routti sold 12,000 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $47.25, for a total value of $567,000.00. Following the sale, the director now owns 133,840 shares in the company, valued at approximately $6,323,940. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 399,982 shares of company stock worth $21,250,362. Company insiders own 13.60% of the company’s stock.

FibroGen, Inc (FGEN) opened at $44.85 on Thursday. FibroGen, Inc has a twelve month low of $19.25 and a twelve month high of $60.15. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16.

ILLEGAL ACTIVITY NOTICE: “5,556 Shares in FibroGen, Inc (FGEN) Acquired by BBR Partners LLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/07/5556-shares-in-fibrogen-inc-fgen-acquired-by-bbr-partners-llc.html.

FibroGen Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.